S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)

Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

$2.75
-0.02 (-0.72%)
(As of 09:30 AM ET)
Today's Range
$2.75
$2.75
50-Day Range
$2.41
$3.09
52-Week Range
$2.16
$4.65
Volume
695 shs
Average Volume
80,882 shs
Market Capitalization
$344.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Nautilus Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
118.2% Upside
$6.00 Price Target
Short Interest
Healthy
2.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$108,316 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.72) to ($0.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.77 out of 5 stars

Medical Sector

708th out of 939 stocks

Analytical Instruments Industry

20th out of 28 stocks

NAUT stock logo

About Nautilus Biotechnology Stock (NASDAQ:NAUT)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

NAUT Stock Price History

NAUT Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Q4 2023 Nautilus Biotechnology Inc Earnings Call
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Nautilus Biotechnology Inc Ordinary Shares
Nautilus Biotechnology Inc.
See More Headlines
Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NAUT
Fax
N/A
Employees
167
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+116.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-63,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.12 per share

Miscellaneous

Free Float
71,931,000
Market Cap
$346.53 million
Optionable
Optionable
Beta
1.17
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives


NAUT Stock Analysis - Frequently Asked Questions

Should I buy or sell Nautilus Biotechnology stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares.
View NAUT analyst ratings
or view top-rated stocks.

What is Nautilus Biotechnology's stock price target for 2024?

1 brokerages have issued 1-year price targets for Nautilus Biotechnology's shares. Their NAUT share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 118.2% from the stock's current price.
View analysts price targets for NAUT
or view top-rated stocks among Wall Street analysts.

How have NAUT shares performed in 2024?

Nautilus Biotechnology's stock was trading at $2.99 at the beginning of 2024. Since then, NAUT shares have decreased by 8.0% and is now trading at $2.75.
View the best growth stocks for 2024 here
.

When is Nautilus Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our NAUT earnings forecast
.

How were Nautilus Biotechnology's earnings last quarter?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) announced its earnings results on Wednesday, February, 28th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. During the same period last year, the company earned ($0.11) earnings per share.

Who are Nautilus Biotechnology's major shareholders?

Nautilus Biotechnology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (10.08%), Vanguard Group Inc. (2.26%), Vanguard Group Inc. (2.26%), Dimensional Fund Advisors LP (0.32%), Nuveen Asset Management LLC (0.15%) and Charles Schwab Investment Management Inc. (0.11%). Insiders that own company stock include Anna Mowry, Gwen E Weld, Life Sciences Maste Perceptive, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc, Subramanian Sankar and Sujal M Patel.
View institutional ownership trends
.

How do I buy shares of Nautilus Biotechnology?

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NAUT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners